IL2RA and extranodal nasal NK/T cell lymphoma: On the basis of PR after treatment with an anti-CD25 mAb basiliximab, plus pegaspargase in a patient with relapsed NKTCL [32], a phase 2 clinical trial of basiliximab plus pegaspargase is currently ongoing in NKTCL patients (NCT04337593).